1. Respiratory Bioinformatics and Molecular Biology, School of Life Sciences, University of Technology Sydney, Sydney, New South Wales, Australia;
2. Groningen Research Institute for Asthma and COPD,
3. Department of Pulmonary Diseases, and
4. Centre for Inflammation, Faculty of Science, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia;
5. Department of Pathology & Medical Biology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands;
6. Centre for Computational Biology, Mines ParisTech, Paris Sciences et Lettres Research University, Paris, France;
7. Cancer and Genome: Bioinformatics, Biostatistics and Epidemiology of Complex Systems Institut Curie, Paris, France;
8. Institut Nationale de la Santé et de la Recherche Médicale U900, Paris, France;
9. Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany;
10. Institute for Computational Cancer Biology, Center for Integrated Oncology, Cancer Research Center Cologne Essen, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany;
11. Berlin Institute for the Foundations of Learning and Data, Berlin, Germany;
12. National Heart & Lung Institute, Imperial College London, London, United Kingdom;
13. Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands;
14. Sanofi, Chilly-Mazarin, France;
15. Sanofi, Cambridge, Massachusetts;
16. Regeneron Pharmaceuticals, Tarrytown, New York;
17. Centre for Asthma & Respiratory Disease, The University of Newcastle, Newcastle, New South Wales, Australia; and
18. Hunter Medical Research Institute, Vaccines, Infection, Viruses & Asthma Newcastle, New South Wales, Australia